Nephrology

📚 02 Pediatric Superspecialities • 🎯 154 High-Yield MCQs • Nelson 22nd Edition Standard

Renal Function Assessment, Glomerulonephritis, & RPGN

  • Glomerular Filtration Rate (GFR) Estimation in Children: ((NEPH001)): In acute kidney injury and dehydration, use the modified bedside Schwartz formula: $eGFR = 0.413 \times \frac{\text{height (cm)}}{\text{serum creatinine (mg/dL)}}$. Do not use adult formulas like Cockcroft-Gault, MDRD, or CKD-EPI (Cystatin C) for standard pediatric bedside estimations ((NEPH001)).
  • Crescentic Glomerulonephritis (RPGN): ([NEPH002, DX_001, DX_002]): Crescents in Bowman's space are pathognomonic for rapidly progressive glomerulonephritis (RPGN), composed of proliferating parietal epithelial cells, fibrin, and macrophages ((NEPH002)). Post-infectious glomerulonephritis is the most frequent cause of pediatric crescentic GN ((NEPH006)). ANCA-associated vasculitis and systemic lupus erythematosus also predominate in older children/adolescents ((NEPH032)).
  • Hemoglobinuria vs. Myoglobinuria: ((NEPH003)): Both yield red/brown urine with a positive dipstick for blood but 0 RBCs on microscopy. Differentiate by assessing serum creatine kinase (CK) and plasma color: myoglobinuria presents with markedly elevated CK and clear plasma; hemoglobinuria presents with reddish plasma and normal CK ((NEPH003)).

Glomerular Diseases & Syndromes

  • Alport Syndrome: ((NEPH004)): Caused predominantly by mutations in the COL4A5 gene encoding the $\alpha5$ chain of type IV collagen (X-linked, ~70–80% of cases) ((NEPH004)). Associated with sensorineural hearing loss, anterior lenticonus, and GBM thinning, splitting, and alternating lamellation. COL4A3 and COL4A4 mutations are autosomal ((NEPH004)).
  • Complement Profiles in Glomerulonephritis: ((NEPH005)): - Low/Consumptive C3 (Normal C4): Characteristic of Acute Post-Streptococcal Glomerulonephritis (APSGN) (normalizes in 6–8 weeks), membranoproliferative GN (MPGN), and lupus nephritis ((NEPH005)). - Normal C3 & C4 Levels: Hallmark of IgA nephropathy, which classically presents with synpharyngitic hematuria (coincident with mucosal infections) ((NEPH005)).
  • Lupus Nephritis & Plasmapheresis: ((NEPH007)): Plasmapheresis is not indicated for isolated proliferative lupus nephritis. It is reserved for life-threatening complications like coexisting thrombotic thrombocytopenic purpura (TTP) or ANCA-associated vasculitis with pulmonary hemorrhage, and anti-GBM disease [NEPH007, DX_003].
  • Goodpasture Syndrome (Anti-GBM Disease): ((NEPH031)): Triad of hemoptysis, rapidly progressive renal failure, and normal complements. Biopsy reveals linear IgG and C3 deposition along the GBM on immunofluorescence with no electron-dense deposits on electron microscopy ((NEPH031)).
  • IgA Vasculitis (Henoch-Schönlein Purpura) Nephritis: ((((NEPH008)) · ((NEPH033)))): Kidney involvement occurs in 30–50% of cases (higher in children >8 years) ((NEPH008)). Most patients with nephritis present with urinary abnormalities (hematuria/proteinuria) ((NEPH033)). Severity of rash/GI symptoms does not predict nephritis severity ((NEPH033)). Perform weekly urinalysis and BP checks for at least 3–6 months ((NEPH008)).

Tubulointerstitial Diseases & Nephrotoxins

  • Nephrotoxic Tubular Injury vs. Glomerular Drugs: ((NEPH009)): Amphotericin B (causes RTA/ATN), ifosfamide (proximal tubule/Fanconi), and cyclosporine (tubular injury/interstitial fibrosis) cause primary tubular toxicity. Penicillamine causes glomerular injury (minimal change disease or membranous nephropathy), not tubular toxicity ((NEPH009)).
  • Acute Tubulointerstitial Nephritis (ATIN): ((NEPH010)): Primarily a T-cell-mediated hypersensitivity reaction most commonly triggered by drugs (NSAIDs, penicillins, cephalosporins, sulfonamides) in children ((NEPH010)).

Ciliopathies, Cystic Kidneys, & Congenital Anomalies

  • Joubert Syndrome / Nephronophthisis: ((NEPH011)): A nephronophthisis-related ciliopathy characterized by developmental delay, hypotonia, and the pathognomonic molar tooth sign on brain MRI due to cerebellar vermis hypoplasia ((NEPH011)).
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): ((NEPH016)): Caused by mutations in PKD1 (chromosome 16; ~85%, severe course), PKD2 (chromosome 4; ~10-15%, milder), and GANAB ((NEPH016)). NPHS2 (podocin) causes steroid-resistant nephrotic syndrome, not ADPKD ((NEPH016)).
  • Potter Sequence: ((NEPH015)): Caused by profound oligohydramnios (secondary to bilateral renal agenesis or severe hypoplasia) leading to fetal compression: pulmonary hypoplasia, low-set ears, micrognathia, and limb deformities ((NEPH015)).

Hemolytic Uremic Syndrome (HUS)

  • STEC-HUS vs. Atypical HUS: ((((NEPH012)) · ((NEPH034)))): - Shiga toxin-producing E. coli (STEC) HUS: Most common pediatric HUS; diarrhea-associated with a favorable prognosis (<5% mortality, high rate of complete kidney recovery) ((NEPH012)). - Atypical HUS (aHUS): Caused by alternative complement pathway dysregulation. Implicated genetic variants include Complement Factor H (CFH), Factor I (CFI), Factor B (CFB), C3, and MCP (CD46). Complement Factor D is not classically implicated ((NEPH034)).

Vascular Renal Disorders

  • Nutcracker Syndrome: ((NEPH013)): Caused by compression of the left renal vein (not the renal artery) between the aorta and the superior mesenteric artery, leading to left renal venous hypertension, gross/microscopic hematuria, and left flank pain ((NEPH013)).

Tubular Disorders, RTA, & Electrolyte Syndromes

  • Hypercalciuria Cutoffs: ((NEPH014)): Diagnosed when 24-hour urinary calcium excretion exceeds >4 mg/kg/day, or a spot urine calcium-to-creatinine (Ca:Cr) ratio is >0.2 in children >1 year ((NEPH014)).
  • Renal Tubular Acidosis (RTA) & Urine Anion Gap: ((NEPH023)): - Distal RTA (Type 1): Impaired $H^+$ excretion and defective ammoniagenesis leads to a positive urine anion gap [$(Na^+ + K^+) - Cl^-$] and urine pH > 5.5 ((NEPH023)). - Proximal RTA (Type 2): Intact ammoniagenesis yields a negative urine anion gap and variable urine pH.
  • Bartter Syndrome Type IV: ((NEPH024)): Caused by mutations in BSND, CLCNKA, or CLCNKB, presenting with classic hypokalemic metabolic alkalosis accompanied by sensorineural hearing loss ((NEPH024)).
  • Liddle Syndrome: ((NEPH025)): Gain-of-function mutation in the epithelial sodium channel (ENaC) causing severe hypertension, hypokalemia, metabolic alkalosis, and suppressed renin and aldosterone levels ((NEPH025)). Responsive to amiloride, resistant to thiazides ((NEPH025)).
  • Fanconi Syndrome Etiologies: ((NEPH026)): Global proximal tubule dysfunction caused by ifosfamide, aristolochic acid, ciprofloxacin, tenofovir, and lead. Metronidazole does not cause Fanconi syndrome ((NEPH026)).

Diuretics & Pharmacology

  • Loop Diuretics Site of Action: ((NEPH027)): Furosemide acts on the $\text{Na}^+-\text{K}^+-2\text{Cl}^-$ cotransporter in the thick ascending limb of the loop of Henle (TALH) ((NEPH027)).

Hypertension & CKD Management

  • Pediatric Hypertension (AAP 2017 Guidelines): ((NEPH028)): Stage 2 Hypertension in children <13 years is defined as BP $\ge 95^{\text{th}}$ percentile + 12 mmHg, or $\ge 140/90$ mmHg (whichever is lower) ((NEPH028)).
  • Antiproteinuric Therapy in CKD: ((NEPH029)): Proteinuria is a modifiable risk factor driving CKD progression. The therapeutic target is to reduce proteinuria to $<300\text{ mg/m}^2/\text{day}$ using ACE inhibitors or ARBs ((NEPH029)).

Renal Replacement Therapy (RRT)

  • Peritoneal Dialysis (PD) in Pediatrics: ((NEPH030)): Ideal for neonates/infants due to vascular access sparing and minimal equipment needs. However, PD has less precise ultrafiltration control compared to hemodialysis or CRRT in unstable, fluid-overloaded patients ((NEPH030)).

Nephrotic Syndrome & Complications

  • Proteinuria Quantification Metrics: ((NEPH018)): - Normal 24-hour protein excretion is $<150\text{ mg/m}^2/\text{day}$ (not $<300\text{ mg/day}$) ((NEPH018)). - Nephrotic-range proteinuria: Spot urine protein-to-creatinine ratio $>2\text{ mg/mg}$ (in children >2 years) ((NEPH018)). - Microalbuminuria: Urinary albumin $>30\text{ mg/g}$ creatinine ((NEPH018)).
  • Spontaneous Bacterial Peritonitis (SBP) in Nephrotic Syndrome: ((NEPH019)): Most frequently caused by Streptococcus pneumoniae (Pneumococcus) due to urinary immunoglobulin loss and complement deficiency ((NEPH019)).
  • Minimal Change Nephrotic Syndrome (MCNS): ((NEPH020)): Accounts for ~85-90% of pediatric nephrotic syndrome; demonstrates the highest steroid responsiveness with ~90% achieving remission after 8 weeks of oral corticosteroids ((NEPH020)).
  • Vaccination Protocols in Nephrotic Syndrome: ((NEPH021)): - Live vaccines are contraindicated during active immunosuppression; defer until prednisone doses are below $<1\text{ mg/kg/day}$ or $<2\text{ mg/kg}$ alternate-day ((NEPH021)). - Household contacts should receive live vaccines (e.g., varicella, MMR) to protect the immunosuppressed child, avoiding direct contact with secretions for 3–6 weeks ((NEPH021)).
  • Congenital Nephrotic Syndromes: ((NEPH022)): - Galloway-Mowat Syndrome: Triad of congenital nephrotic syndrome, microcephaly, and hiatal hernia with kidney biopsy showing poor basement membrane formation / absent fibrils ((NEPH022)). - Denys-Drash Syndrome: Caused by WT1 mutations; presents with ambiguous genitalia, Wilms tumor, and diffuse mesangial sclerosis ((NEPH022)).

Acute Kidney Injury & Tubular Disorders

  • Acute Tubular Necrosis (ATN) & Furosemide: ((NEPH036)): In established oliguric ATN with volume overload, furosemide may convert oliguric ATN to a nonoliguric form, facilitating fluid, electrolyte, and nutritional management; however, it does not accelerate tubular epithelial recovery, alter the overall clinical course, or improve long-term renal outcome.
  • Acute Tubulointerstitial Nephritis (ATIN): ((NEPH065)): Drug-induced ATIN (classically linked to amoxicillin-clavulanate) presents with fever, eosinophilia, sterile pyuria, and AKI. Mandatory first-step action is to discontinue the suspected offending drug; corticosteroids are reserved for non-responders.
  • Pediatric AKI Staging (KDIGO): ((NEPH063)): Stage 2 AKI is defined by a 2.0 to 2.9-fold increase in serum creatinine from baseline OR urine output < 0.5 mL/kg/h for ≥12 hours.

Renal Tubular Acidosis & Inherited Tubulopathies

  • Dent Disease: ((NEPH041)): X-linked recessive proximal tubulopathy caused predominantly by pathogenic variants in CLCN5. Characterized by low molecular weight proteinuria, hypercalciuria, hypercalciuric nephrolithiasis, and hypophosphatemic rickets; proximal RTA is typically absent.
  • Bartter Syndrome: ((NEPH062)): Inherited tubular defect in the thick ascending limb of the loop of Henle presenting with hypokalemia, metabolic alkalosis, normal blood pressure, and elevated urinary calcium-to-creatinine ratio (hypercalciuria) distinguishing it from Gitelman syndrome (which has hypocalciuria).
  • Lowe Syndrome: ((NEPH067)): X-linked oculocerebrorenal syndrome caused by mutations in OCRL1. Characterized by congenital cataracts, central hypotonia with developmental delay, and Fanconi syndrome (low molecular weight proteinuria, glycosuria, aminoaciduria, phosphaturia, and nephrocalcinosis).

Cystic & Genetic Renal Diseases

  • Autosomal Recessive Polycystic Kidney Disease (ARPKD): ([NEPH037, __NEPH056__]): Caused by mutations in the PKHD1 gene (fibrocystin). Natural history reveals that approximately 40% exhibit the severe kidney/severe liver phenotype, with the remaining three phenotype combinations occurring in 20% each. Presents with bilaterally enlarged echogenic kidneys and universal hepatic fibrosis.
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): ((NEPH057)): Caused by PKD1 (chromosome 16) or PKD2 mutations. A normal renal ultrasound by age 20 years in at-risk individuals carries a 95% chance of excluding the disease.
  • Nephropathic Cystinosis: ((NEPH040)): Caused by biallelic pathogenic variants in CTNS (cystinosin transporter). Oral cysteamine depletes systemic tissue cystine but fails to adequately penetrate ocular tissues; therefore, cysteamine eye drops are mandatory to treat corneal crystals and photophobia.
  • Von Hippel-Lindau (VHL) Syndrome: ((NEPH066)): Autosomal dominant neoplastic disorder due to germline mutations in the VHL tumor suppressor gene on chromosome 3p25.3, manifesting with retinal/cerebellar hemangioblastomas, renal cysts, and clear-cell renal cell carcinoma.

Glomerular Diseases & Nephrotic Syndrome

  • Steroid-Sensitive Nephrotic Syndrome (SSNS) Initial Treatment: ((NEPH059)): Standard induction therapy is prednisolone 60 mg/m²/day (or 2 mg/kg/day) daily for 4–6 weeks followed by 40 mg/m²/dose on alternate days for 4–6 weeks with no taper during the alternate-day phase.
  • Congenital Nephrotic Syndrome (CNS): ((NEPH060)): Presents within the first 3 months of life due to slit-diaphragm structural defects. Caused by mutations in NPHS1 (nephrin), NPHS2 (podocin), and WT1 (Denys-Drash/Frasier). (PKHD1 causes ARPKD, not CNS).
  • Cyclophosphamide Toxicity & Monitoring: ((NEPH039)): Used for steroid-dependent nephrotic syndrome. Requires weekly white blood cell monitoring; the drug must be withheld if the WBC count falls below 5,000/mm³ due to severe myelosuppression.
  • IgA Nephropathy & Management: ([NEPH047, __NEPH068__]): Most common chronic glomerular disease presenting classically with synpharyngitic gross hematuria (coinciding with mucosal infections). For patients with persistent significant proteinuria despite optimized RAS blockade and GFR > 60 mL/min/1.73 m², add corticosteroid therapy.
  • Post-Streptococcal Glomerulonephritis (APSGN): ([NEPH049, __NEPH070__]): Characterized by hypocomplementemia (low C3) and a strong immunogenetic association with HLA-B12. Severe hypertension can precipitate hypertensive encephalopathy (seizures, altered sensorium).
  • Alport Syndrome vs. MYH9 Disorders: ([NEPH048, __NEPH069__]): Classic Alport syndrome (COL4A3, COL4A4, COL4A5) presents with hematuria, sensorineural hearing loss, and GBM splitting/lamellation. When associated with macrothrombocytopenia and giant platelets, the diagnosis shifts to an MYH9-related disorder (Fechtner/Epstein syndrome).
  • Lupus Nephritis Class III/IV Induction: ((NEPH051)): Standard induction protocol consists of six monthly intravenous infusions of cyclophosphamide (500–1000 mg/m²)加上 corticosteroids.
  • HIV-Associated Nephropathy (HIVAN): ((NEPH050)): Characterized by nephrotic-range proteinuria, renal dysfunction, and enlarged echogenic kidneys. Hallmark histopathology is Focal Segmental Glomerulosclerosis (FSGS) - collapsing variant.

Renal Vascular, Systemic, & Transplantation Notes

  • Atypical Hemolytic Uremic Syndrome (aHUS): ((NEPH053)): Frequently linked to complement regulatory mutations (e.g., complement factor H). Treatment with eculizumab (terminal complement C5 inhibitor) requires mandatory pre-treatment meningococcal vaccination due to increased encapsulated organism susceptibility.
  • Contrast-Induced Nephropathy (CIN): ((NEPH054)): Following iodinated contrast exposure, serum creatinine typically peaks within 24-48 hours and spontaneously normalizes within 3 to 7 days in children with normal baseline renal function.
  • Sickle Cell Nephropathy: ((NEPH055)): Vaso-occlusion in the renal medulla (low oxygen tension, acidic environment) leads to ischemia, papillary necrosis, and interstitial fibrosis, presenting clinically with hyposthenuria, microscopic hematuria, and proteinuria.
  • Native Nephrectomy Indications Pre-Transplant: ((NEPH045)): Indicated for oncologic risk (e.g., Denys-Drash syndrome / Wilms tumor risk), severe treatment-resistant hypertension, and hyposthenuria with massive polyuria; IgA nephropathy recurrence risk is not an indication.
  • Nephrogenic Systeic Fibrosis (NSF): ((NEPH046)): Historically linked to the administration of linear gadolinium-based contrast agents in patients with advanced CKD/ESKD; newer macrocyclic agents carry substantially lower risk.

Glomerular Diseases & Complement Pathologies

  • Post-Infectious GN vs. Membranoproliferative GN (MPGN): ((NEPH071)): Persistent hypocomplementemia (low C3) beyond 6–8 weeks is atypical for poststreptococcal GN and mandates evaluation for MPGN, lupus nephritis, shunt nephritis, or mixed cryoglobulinemia. IgA nephropathy classically presents with recurrent synpharyngitic hematuria and typically has normal serum complement levels.
  • Dense Deposit Disease (MPGN Type II): ((NEPH072)): Diagnosed by markedly reduced C3 with normal C4, dominant C3 deposition without immunoglobulins, and dense transformation of the lamina densa on EM. Strongly associated with partial lipodystrophy and dysregulation of the alternative complement pathway via C3 nephritic factor. Type I MPGN features both C3 and immunoglobulin deposition with subendothelial/mesangial deposits.
  • Class V Lupus Nephritis (Membranous): ((NEPH073)): Presents with nephrotic-range proteinuria, minimal hematuria, and bland urinary sediment with preserved renal function and mild lupus serologic activity. Biopsy shows diffuse thickening of glomerular capillary walls without proliferation.
  • Induction Therapy in Proliferative Lupus Nephritis (Class IV): ((NEPH074)): Requires aggressive therapy like mycophenolate mofetil (MMF) combined with corticosteroids. MMF is preferred over cyclophosphamide in pediatric patients to avoid gonadal failure and hemorrhagic cystitis; especially efficacious in Black patients. (Pediatric dose: 600 mg/m² per dose twice daily).
  • Infection-Associated Glomerulonephritis: ((NEPH075)): Caused by chronic persistent antigenemia (malaria, schistosomiasis, leishmaniasis, filariasis, trypanosomiasis). Enterobius vermicularis is least likely to cause immune complex-mediated glomerular disease.
  • Long-term Maintenance in SLE: ((NEPH076)): Hydroxychloroquine is standard for extrarenal manifestations and assists in maintaining lupus nephritis remission due to a favorable safety profile (does not replace induction/maintenance immunosuppression).
  • Atypical Pediatric Nephrotic Presentation: ((((NEPH077)) · ((NEPH091)))): Nephrotic syndrome with atypical features (persistent hypertension, microscopic hematuria, hypocomplementemia, and sustained creatinine elevation) mandates a renal biopsy before starting therapy.

Hemolytic-Uremic Syndrome (HUS) & Thrombotic Microangiopathy

  • Complications of HUS: ((NEPH077)): Multisystem endothelial injury causes encephalopathy, seizures, ischemic enteritis, bowel perforation, intussusception, and pancreatitis. While petechiae occur, severe spontaneous bleeding is uncommon despite marked thrombocytopenia.
  • Drug-Induced HUS Causes: ((NEPH078)): Caused by calcineurin inhibitors (tacrolimus, cyclosporine), antineoplastics (cisplatin, bleomycin), and quinine. Methotrexate is not a recognized cause of drug-induced HUS.
  • Pneumococcal-Associated HUS Contraindication: ((NEPH079)): Plasma infusion/plasmapheresis is strictly contraindicated because donor plasma contains natural antibodies against the exposed Thomsen-Friedenreich (T) antigen (exposed by pneumococcal neuraminidase), which drastically worsens hemolysis and thrombosis.

Renal Tubular Acidosis (RTA) & Tubular Defects

  • Acquired RTA Toxins: ((NEPH080)): Amphotericin B, toluene, lithium, and lead cause normal anion gap metabolic acidosis (Type 1 or 2 RTA). Ethylene glycol is a mimic that causes a high anion gap metabolic acidosis with calcium oxalate crystalluria.
  • NSAID-Induced Interstitial Nephritis: ((NEPH081)): Acute tubulointerstitial nephritis usually presents with pyuria, WBC casts, and rising creatinine without marked proteinuria. NSAIDs are a notable exception, frequently presenting with nephrotic-range proteinuria and fewer classic hypersensitivity manifestations.
  • Fanconi Syndrome Systemic Associations: ((NEPH094)): Caused by generalized proximal tubular dysfunction. Associated with cystinosis, Lowe syndrome, Wilson disease, Fanconi-Bickel syndrome, tyrosinemia, galactosemia, and methylmalonic acidemia. Ornithine transcarbamylase (OTC) deficiency causes hyperammonemia but not Fanconi syndrome.
  • Distal RTA (Type 1) Pathophysiology: ((NEPH095)): Impaired $H^+$ excretion leads to chronic metabolic acidosis and hypocitraturia. Since citrate binds calcium and inhibits crystals, hypocitraturia coupled with hypercalciuria drives nephrocalcinosis and nephrolithiasis.
  • Proximal RTA Management: ((((NEPH096)) · ((NEPH097)))): Characterized by bicarbonate and phosphate wasting leading to rickets. Treatment requires bicarbonate replacement, oral phosphate, and vitamin D. Correcting acidosis alone is insufficient without replacing lost phosphate.
  • Medullary Sponge Kidney: ((NEPH096)): Cystic dilation of terminal collecting ducts presenting with nephrocalcinosis, nephrolithiasis, hyposthenuria, and distal RTA. Strongly associated with hemihypertrophy (Beckwith-Wiedemann syndrome).

Inherited Ciliopathies & Cystic Kidney Diseases

  • Nephronophthisis & Extrarenal Associations: ((((NEPH082)) · ((NEPH083)))): Autosomal recessive ciliopathy causing polyuria, growth failure, bland sediment, and ESRD.
  • Senior-Løken syndrome: : Nephronophthisis + retinal degeneration/retinitis pigmentosa.
  • Macular flecks, recurrent corneal erosions, and sensorineural hearing loss: point to Alport syndrome (type IV collagen defect), not nephronophthisis.
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): ((((NEPH088)) · ((DX090)))): Caused by PKD1 (~85%) and PKD2 (10-15%). PKD1/PKD2-negative ADPKD cases are linked to mutations in GANAB. Asymptomatic ADPKD patients with a family history of intracranial aneurysms should be screened using MR angiography around 18 years of age.
  • Zellweger Syndrome: ((NEPH089)): Peroxisomal biogenesis disorder (PEX gene mutations) presenting with hypotonia, seizures, craniofacial dysmorphism, hepatomegaly, renal cortical microcysts, and intrahepatic biliary dysgenesis.

Vascular, Malignancy, & Electrolyte Renal Disorders

  • Renal Papillary Necrosis: ((NEPH084)): Ischemic necrosis of medullary pyramids seen in sickle cell disease. CT reveals medullary clefts, pelvic filling defects, and ring-like contrast collections.
  • Neonatal Renal Vein Thrombosis: ((NEPH085)): Requires long-term pediatric nephrology follow-up even if infant serum creatinine normalizes, due to high risk of silent late-onset renal atrophy, tubular dysfunction, and hypertension.
  • Renal Medullary Carcinoma: ((NEPH086)): Highly aggressive renal malignancy strongly associated with sickle cell trait rather than sickle cell disease itself.
  • Idiopathic Hypercalciuria Management: ((NEPH087)): Dietary sodium restriction parallels and lowers urinary calcium excretion. Routine calcium restriction is contraindicated as it impairs skeletal growth and worsens bone mineral density.
  • Lithium-Induced Nephrogenic DI: ((NEPH099)): Lithium enters principal cells via ENaC. Treatment with amiloride specifically blocks ENaC channels, halting lithium entry.
  • Evaluating Polyuria/Hypernatremia: ((NEPH100)): If serum osmolality is $\ge$290 mOsm/kg with an inappropriately low urine osmolality, a concentrating defect is confirmed; water deprivation is skipped, and exogenous desmopressin is given directly to differentiate central vs. nephrogenic DI.
  • EAST Syndrome: ((NEPH101)): Autosomal recessive mutation in KCNJ10 (Kir4.1 channel) featuring Epilepsy, Ataxia, Sensorineural deafness, and Tubulopathy (hypokalemic metabolic alkalosis).

Acute Kidney Injury & Rhabdomyolysis

  • KDIGO Staging Rule: ((NEPH102)): AKI is staged using the highest stage reached by either serum creatinine or urine output criteria. (e.g., Stage 2 SCr rise + Stage 3 urine output oliguria = Stage 3 AKI).
  • Rhabdomyolysis & Myophosphorylase Deficiency: ((NEPH103)): Exercise-induced myoglobinuria causes heme-positive urine without RBCs. Myophosphorylase deficiency (McArdle disease) is a classic inherited cause.
  • Acute Tubular Necrosis (ATN) Sediment: ((NEPH104)): The hallmark urinary sediment finding of ATN is broad muddy-brown granular casts, which are more reliable than fractional excretion indices in settings like sepsis.
  • CRRT Modalities: ((NEPH105)): Continuous venovenous hemodiafiltration (CVVHDF) utilizes simultaneous convection (via replacement fluid ultrafiltration) and diffusion (via countercurrent dialysate flow) for maximum solute and fluid clearance.

Chronic Kidney Disease (CKD) & Mineral Bone Disease

  • Nutritional Management in Pediatric CKD: ((NEPH106)): Dietary protein restriction is not recommended in children with CKD as it impairs growth and lean body mass. Protein intake must be maintained at 100% of the dietary reference intake (DRI) for ideal body weight alongside adequate caloric intake. Children on dialysis require even higher protein intake due to dialytic losses.
  • Adynamic Renal Osteodystrophy: ((NEPH107)): Low-turnover bone disease characterized by hypercalcemia, markedly suppressed PTH, and low alkaline phosphatase activity, typically seen in pediatric dialysis patients. This contrasts with osteitis fibrosa cystica, which features elevated PTH and alkaline phosphatase.
  • Vitamin D Sterols in Secondary Hyperparathyroidism: ((NEPH108)): Paricalcitol is preferred over calcitriol in advanced CKD with persistent secondary hyperparathyroidism when recurrent hypercalcemia limits calcitriol use, as it suppresses PTH with less intestinal calcium and phosphorus absorption.
  • Growth Failure in CKD: ((NEPH109)): CKD causes a functional growth hormone (GH)-resistant state with normal/elevated GH and reduced IGF-1 activity. Recombinant human growth hormone (rhGH) is indicated when height remains below $-2$ SD and growth velocity is $<25\text{th percentile}$ for $>6$ months despite optimal management of nutrition, anemia, acidosis, and CKD-MBD.

Hypertension & Renal Transplantation

  • Hypertension Management in CKD: ((NEPH110)): Pharmacologic therapy is indicated when blood pressure exceeds the 90th percentile. An angiotensin receptor blocker (ARB) like losartan or an ACE inhibitor is first-line to reduce intraglomerular pressure and proteinuria. Blood pressure should be titrated to $<50\text{th percentile}$ in the presence of persistent proteinuria.
  • Preemptive Kidney Transplantation: ((NEPH111)): The preferred renal replacement modality for pediatric stage 4/5 CKD when GFR decline is anticipated within 6–12 months or when CKD severely impacts growth, health, or neurocognition.
  • Disease Recurrence in Allografts: ((NEPH112)): Alport syndrome (type IV collagen defect) has the most favorable disease-specific outcome with virtually 0% recurrence in the allograft (though a rare 3-4% may develop de novo anti-GBM disease). Conversely, focal segmental glomerulosclerosis (FSGS) recurs in 30-60% of cases.
  • Primary Hyperoxaluria & Hepatic Silencing: ((NEPH113)): Lumasiran is an RNA interference therapy targeting the HAO1 gene (glycolate oxidase) to directly reduce hepatic oxalate production, potentially modifying combined liver-kidney transplantation requirements.
  • Induction Immunosuppression Agents: ((((NEPH114)) · ((NEPH115)))):
  • Basiliximab: : Chimeric monoclonal antibody targeting CD25 (IL-2 receptor $\alpha$-chain) on activated T cells, inhibiting proliferation without T-cell depletion. - Alemtuzumab: Targets CD52, causing profound lymphocyte depletion.
  • Tacrolimus vs. Cyclosporine: : Tacrolimus is preferred for rejection/cosmetic profiles, but carries a higher risk of new-onset diabetes after transplantation (NODAT), prompting conversion to cyclosporine if clinically significant.
  • Allograft Complications: ((((NEPH116)) · ((NEPH117)))):
  • BK Polyomavirus Nephropathy: : Presents with unexplained rise in serum creatinine; diagnosed via plasma BK PCR and allograft biopsy showing viral cytopathic changes; treated by reducing immunosuppression.
  • Acute Rejection in Pediatric Recipient of Adult Kidney: : Substantial renal functional reserve means acute T-cell-mediated rejection can present with new-onset hypertension or proteinuria with normal serum creatinine.

Glomerular Diseases

  • IgA Nephropathy: ((NEPH118)): Characterized by recurrent gross hematuria triggered concurrently by mucosal (upper respiratory/GI) infections. Biopsy shows mesangial hypercellularity and matrix expansion with IgA-dominant immune deposits.
  • Post-Streptococcal Glomerulonephritis (PSGN): ((NEPH119)): Occurs 1–3 weeks after skin (impetigo) or pharyngeal streptococcal infection. Electron microscopy reveals pathognomonic large subepithelial immune complex "humps" (IgG and C3). Serum C3 is low.
  • Anti-GBM Disease (Goodpasture Syndrome): ((NEPH120)): Presents with rapidly progressive glomerulonephritis and pulmonary hemorrhage (hemoptysis). Immunofluorescence shows linear IgG deposition along the glomerular basement membrane (GBM) against the noncollagenous domain of type IV collagen.
  • Focal Segmental Glomerulosclerosis (FSGS): ((NEPH122)): Common cause of steroid-resistant nephrotic syndrome in older children. Histology reveals segmental sclerosis, hyalinosis, and podocyte foot process effacement.
  • Rapidly Progressive Glomerulonephritis (RPGN) & Crescents: ((NEPH124)): Cellular crescents in Bowman's space are the hallmark of severe glomerular injury and RPGN, formed by the proliferation of parietal epithelial cells and infiltration by monocytes/macrophages.
  • Membranous Nephropathy (MN): ((NEPH127)): Immune complex-mediated nephropathy in older children. Associated with anti-phospholipase A2 receptor (PLA2R) antibodies on podocytes. Light microscopy shows thickened GBM; immunofluorescence shows granular IgG and C3. Complement levels ($C_3, C_4$) are typically normal (unlike lupus or PSGN).
  • Alport Syndrome: ((NEPH128)): X-linked (COL4A5) or autosomal defects in type IV collagen. Presents with persistent microscopic hematuria, progressive proteinuria, and sensorineural hearing loss. Electron microscopy shows the characteristic basket-weave appearance (irregular thickening, thinning, splitting, and lamellation of the GBM).

Cystic & Tubular Disorders

  • Autosomal Recessive Polycystic Kidney Disease (ARPKD): ((NEPH121)): Infantile presentation with bilateral massive nephromegaly, oligohydramnios (Potter sequence), and pulmonary hypoplasia. Caused by mutations in the PKHD1 gene (fibrocystin).
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD): ((NEPH125)): Can present rarely in early childhood/infancy with bilateral renal enlargement, macrocysts, hypertension, and hematuria, often with a positive family history.
  • Renal Tubular Acidosis (RTA): ((NEPH123)):
  • Classic Distal RTA (Type 1): : Defective distal hydrogen ion secretion. Features hypokalemia, non-anion gap metabolic acidosis, high urine pH ($>5.5$), and medullary nephrocalcinosis/rickets.
  • Proximal RTA (Type 2): : Defective proximal bicarbonate reabsorption caused by mutations in the NBC1 (SLC4A4) gene (Na$^+$-3HCO$_3^-$ cotransporter). Features hypokalemia, non-anion gap metabolic acidosis, but urine pH can drop ($<5.5$) when serum bicarbonate falls below threshold.

Renal Diagnostics & Urinalysis

  • Renal Clearance Calculations: ((NEPH130)): - Clearance formula: $C = \frac{U \times V}{P}$ (where $U$ = urine concentration, $V$ = urine flow rate, $P$ = plasma concentration). Substance must be freely filtered without tubular secretion/reabsorption (e.g., inulin). - BSA Normalization: $\text{Corrected Clearance} = \text{Measured Clearance} \times \frac{1.73}{\text{Patient BSA}}$.
  • Paediatric eGFR Estimation: ((NEPH132)): For routine stable CKD, use height-based creatinine equations such as the bedside Schwartz equation ($\text{eGFR} = \frac{0.413 \times \text{Height (cm)}}{\text{Serum Creatinine (mg/dL)}}$).
  • Heme Pigment vs. True Hematuria: ((NEPH133)):
  • Myoglobinuria/Hemoglobinuria: : Strongly positive dipstick for blood with virtually absent RBCs ($<1-2$ HPF) on microscopy. Myoglobinuria is confirmed by markedly elevated serum creatine kinase (e.g., post-exercise rhabdomyolysis).
  • Pseudohematuria: : Red urine without heme on dipstick and no RBCs caused by foods (blackberries, blueberries, paprika) or drugs (rifampin, phenazopyridine, metronidazole). Cyclophosphamide causes true hematuria (hemorrhagic cystitis) with RBCs.
  • Persistent Asymptomatic Microscopic Hematuria: ((NEPH134)): Isolated microscopic hematuria lasting $>1$ year warrants referral to a pediatric nephrologist, but does not automatically mandate a renal biopsy if blood pressure, renal function, and protein excretion are normal.
  • Proteinuria Evaluation: ((NEPH140)): Dipstick protein is semiquantitative and prone to false positives in concentrated/alkaline urine. A first-morning urine protein-to-creatinine ratio $<0.2$ mg/mg (in children $>2$ years) establishes normal protein excretion and rules out significant proteinuria.

Renal Examination & Imaging

  • Renal Palpation Technique: ((NEPH141)): Bimanual palpation requires supporting the renal angle posteriorly while the anterior hand palpates beneath the costal margin. During inspiration, feel the descending lower pole. Do not maintain deep pressure during expiration, as this traps the kidney and prevents appreciation of its upward movement; instead, reduce anterior pressure during expiration to feel the kidney slip upward. Ballotment uses a brief anteriorly directed impulse from the posterior hand.
  • Exercise-Induced Hematuria: ((NEPH143)): Vigorous exercise causes transient gross/microscopic hematuria with normal red cell morphology and no casts. Mandatory initial approach is to rest and repeat urinalysis after 48 hours. Persistence beyond 48 hours warrants full renal workup.

Nail Findings in Systemic Disease

  • Lindsay's Nails vs. Muehrcke's Lines: ((NEPH142)): Lindsay’s nails (half-and-half nails) show a pale/white proximal half and a darker reddish-brown distal half, highly specific for chronic kidney disease (CKD). Muehrcke’s lines (paired white transverse bands) also occur in renal disease but are driven specifically by hypoalbuminemia. Distractors: Beau's lines represent transverse depressions from temporary cessation of cell division in the nail matrix (systemic stress); Terry's nails show proximal white glass-like nails with a narrow distal pink/brown band (cirrhosis, heart failure).

Proteinuria Evaluation & Orthostatic Proteinuria

  • Orthostatic Proteinuria: ((NEPH144)): Suspected when daytime specimens show significant protein (e.g., 2+) but first-morning urine protein-to-creatinine ratio is normal ($\le 0.2$ mg/mg) with no hematuria. Diagnostic approach: Compare protein excretion during recumbent and upright collection periods.

Nephrotic Syndrome Management & Complications

  • Varicella Vaccination in Household Contacts: ((NEPH145)): Healthy household contacts of immunosuppressed children (e.g., on high-dose steroids for nephrotic syndrome) must receive indicated live vaccines like varicella. Precaution: Avoid direct contact with the vaccinated sibling's secretions for 3–6 weeks. Steroid dose thresholds restrict vaccination of the patient, not healthy household contacts.
  • Definition of Nephrotic Syndrome Relapse: ((NEPH146)): Relapse requires recurrence of nephrotic-range proteinuria defined as urine protein-to-creatinine ratio $>2$ or $\ge 3+$ protein on dipstick for 3 consecutive days. 2 days of 3+ followed by 1 day of 2+ does not fulfill the criteria for established relapse despite intercurrent infections or periorbital edema.
  • Steroid-Resistant Nephrotic Syndrome (SRNS): ((NEPH147)): Defined as failure to achieve remission after 4–6 weeks of glucocorticoids. Next steps: Kidney biopsy, genetic testing, and initiation of calcineurin inhibitors and ACE inhibitors. Cyclophosphamide is contraindicated for initial SRNS as it is reserved for frequently relapsing steroid-sensitive disease.

Renal Tubular Acidosis (RTA) & Electrolyte Disorders

  • Initial Handling of Acidosis Samples: ((NEPH148)): Delayed processing of blood samples left at room temperature causes cellular glycolysis and falsely lowered bicarbonate, mimicking metabolic acidosis. Mandatory first step: Repeat serum electrolytes from an appropriately handled sample before classifying acidosis or investigating RTA.
  • Distal RTA (Classic / Type 1): ((NEPH149)): Characterized by hypokalemic normal-anion-gap metabolic acidosis, nephrocalcinosis, and a positive urine net gap. The fundamental defect is a failure of urinary acidification, resulting in a urine pH persistently $> 5.5$ despite systemic acidemia.
  • Bartter vs. Gitelman Syndromes: ((((NEPH150)) · ((NEPH151)))):
  • Bartter Syndrome: ((NEPH150)): Presents with hypokalemic hypochloremic metabolic alkalosis mimicking vomiting. Differentiated by elevated urinary chloride concentration (renal salt-wasting) vs. low urinary chloride in vomiting. Urinary calcium is characteristically high.
  • Gitelman Syndrome: ((NEPH151)): Presents later with salt craving, muscle cramps, and nocturia. Distinguished by the triad of hypokalemic metabolic alkalosis, hypomagnesemia, and low urinary calcium (hypocalciuria).

Acute & Chronic Kidney Disease Management

  • Emergency Management of Hyperkalemia: ((NEPH152)): When serum potassium rises $>6.0$ mEq/L (e.g., 6.4 mEq/L in oliguric AKI) even with a normal ECG, total body potassium must be reduced. Use sodium polystyrene sulfonate (1 g/kg orally or via retention enema) to exchange sodium for potassium and remove it from the body.
  • Oral Alkali Therapy Dosing: ((NEPH153)): Standard 650 mg sodium bicarbonate tablets deliver 7.7 mEq of sodium and 7.7 mEq of bicarbonate. Prescriptions must account for the substantial associated sodium load.
  • Mineral Bone Disorder in CKD: ((NEPH154)): Pathophysiologic sequence: Phosphate retention $\rightarrow$ reduced serum calcium $\rightarrow$ increased parathyroid hormone (PTH). PTH acts directly on osteoblast-lineage cells, which secondarily stimulate osteoclast differentiation and activity to drive bone resorption.